Live tape
Top 8, mentions 7d30,017NVDA14,564 mentions▲ +0.04ANT4,160 mentions▲ +0.06GOOGL2,936 mentions▲ +0.04SPY2,248 mentions▲ +0.05QQQ1,804 mentions▲ +0.04SPCX1,748 mentions▲ +0.08AMD1,367 mentions▲ +0.06AAPL1,190 mentions▲ +0.04

Equity · Healthcare

DSGN

NASDAQ

Design Therapeutics (DSGN)

11.78 USD −1.83% vs prior close
Design Therapeutics, Inc. price graph

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.

Market cap
754.3M USD
Revenue, year to Dec 2025
0 USD
EPS, diluted, year to Dec 2025
−1.22 USD
52-week range
3.82 USD – 16 USD
Avg volume
206.5K

as of Jul 22, 2026

Have Design Therapeutics (DSGN) insiders bought or sold shares recently?

DSGN's newest Form 4 filing is dated 9 December 2025: none in the last 90 days.

Form 4

Have Design Therapeutics (DSGN) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
09 Dec 2025Shah PratikPresident, CEO and ChairpersonAward525,000

Which funds hold Design Therapeutics (DSGN)?

7 of the 45 institutional funds we track reported a Design Therapeutics position for the quarter ended 30 Sep 2026 — a combined 75.9M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Design Therapeutics (DSGN)?
FundPositionSharesValueShares q/q
Baker Bros. AdvisorsHeld (±25%)2,988,14437.6M USD+11.6%
Point72 Asset ManagementHeld (±25%)2,317,68229.1M USD−2.1%
Renaissance TechnologiesHeld (±25%)301,8003.8M USD−22.2%
D. E. Shaw & Co.Held (±25%)186,0712.3M USD−4.9%
AQR Capital ManagementAdded153,1901.9M USD+115.4%
Citadel AdvisorsHeld (±25%)76,300959K USD−6.9%
Two Sigma InvestmentsTrimmed17,200216K USD−47.8%
Balyasny Asset ManagementExited
Millennium ManagementExited

What has been filed or recorded for Design Therapeutics (DSGN)?

The filings we hold for Design Therapeutics, newest first: 6 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 29 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Design Therapeutics (DSGN)?
And
29 Oct 2026Fails to deliverShares failed to deliver734 shares8K USD notional · 0.001% of shares out
28 Oct 2026Fails to deliverShares failed to deliver4 shares43 USD notional · <0.001% of shares out
19 Oct 2026Fails to deliverShares failed to deliver80,485 shares830K USD notional · 0.126% of shares out
13 Oct 2026Fails to deliverShares failed to deliver618 shares7K USD notional · 0.001% of shares out
09 Oct 2026Fails to deliverShares failed to deliver682 shares8K USD notional · 0.001% of shares out
08 Oct 2026Fails to deliverShares failed to deliver342 shares4K USD notional · 0.001% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −0.32 USD
30 Sep 2026FinancialsTotal assets216.8M USDat period end
30 Sep 2026FinancialsTotal equity202.2M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.32 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.29 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −1.22 USD
31 Dec 2025FinancialsRevenue0 USDfiscal year
31 Dec 2025FinancialsNet income−69.8M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−1.22 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.30 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.34 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.31 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −0.88 USD

What do people ask about Design Therapeutics (DSGN)?

From live data
What is Design Therapeutics’ market cap?754.3M

Design Therapeutics is worth 754.3M USD by market value as of 22 Jul 2026, which is the share price times the shares on issue from its SEC filings.

What is Design Therapeutics’ revenue?0

Design Therapeutics reported revenue of 0 USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Design Therapeutics insiders bought or sold shares recently?

No Design Therapeutics insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 9 Dec 2025 (SEC Form 4). See Insiders

Which funds own Design Therapeutics?7 of 45

7 of the 45 funds we track reported a Design Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Baker Bros. Advisors, Point72 Asset Management and Renaissance Technologies. See Funds

When did Design Therapeutics last report earnings?−0.32

Design Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.32 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings
  9. SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words